Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis

详细信息    查看全文

• 作者：Yan-Ru Ma ; Xiao-Jun Huang ; Zheng-Li Xu ; Kai-Yan Liu ; Huan Chen ; Xiao-Hui Zhang ; Wei Han ; Yu-Hong Chen ; Feng-Rong Wang ; Jing-Zhi Wang ; Yu Wang ; Yao Chen ; Chen-Hua Yan and Lan-Ping Xu
• 刊名：Clinical Transplantation
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：30
• 期：9
• 页码：994-1001
• 全文大小：669K
• ISSN：1399-0012

文摘

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for chronic myeloid leukemia (CML) patients in blast crisis (BC), and haploidentical donors (HID) are immediately available for most patients. We compared the outcomes of HID transplantation with those of matched related donor (MRD) transplantation in a cohort study.